Sector News

Shire considers takeover of Swiss biotech group Actelion -Sunday Times

June 8, 2015
Life sciences
(Reuters) – Pharmaceutical company Shire is considering a 12 billion pound ($18.32 billion) takeover of Actelion Ltd Europe’s biggest biotech firm, Britain’s Sunday Times newspaper reported, citing unnamed sources.
 
An informal approach by Shire was rebuffed several weeks ago, the newspaper said, citing financial industry sources.
 
Shire was willing to pay 160 Swiss francs a share for Actelion, the sources said, a hefty premium to the stock’s Friday closing price of 132 francs.
 
Asked by Reuters for comment, a spokeswoman for Shire said the company did not comment on speculation. An Actelion spokesman said the company did not comment on market rumours.
 
Earlier this year, Actelion raised its full-year guidance after strong sales of its new heart and lung drug helped its first-quarter earnings exceed analysts’ estimates.
 
At the time, the company’s chief executive told Reuters it had not received any outside interest to buy the company.
 
In April, Shire reported a better-than-expected 20 percent rise in first-quarter earnings, helped by the launch of the first drug to treat binge eating disorder.
 
($1 = 0.6549 pounds) (Reporting by William James; additional reporting by Joshua Franklin in Zurich; editing by Jane Merriman and Jason Neely)

comments closed

Related News

April 26, 2024

Former Bristol Myers CEO tapped as Novartis’ next board chair

Life sciences

Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.

April 26, 2024

GE HealthCare launches voice-activated, AI-powered ultrasound machines for women’s health

Life sciences

GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.

April 26, 2024

Scientists reveal new method that could reduce waste from drug manufacturing

Life sciences

Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.

How can we help you?

We're easy to reach